Tempus AI Shares Slide 12% as Q4 Results Disappoint

Investing

25 Feb

Tempus AI reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.

The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.

Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.

"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year," said Eric Lefkofsky, Founder and CEO of Tempus.

For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.

Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1161962625"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161962625\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1161962625?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161962625","market":"us","top_or_hot":-1,"title":"Tempus AI Shares Slide 12% as Q4 Results Disappoint","media":"Investing","content":"<html><head></head><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/f15d2734141482e6aab6365f7e340444\" tg-height=\"392\" tg-width=\"415\"/></p><p style=\"text-align: start;\">The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.</p><p style=\"text-align: start;\">Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.</p><p style=\"text-align: start;\">\"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year,\" said Eric Lefkofsky, Founder and CEO of Tempus.</p><p style=\"text-align: start;\">For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.</p><p style=\"text-align: start;\">Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.</p></body></html>","source":"hk_investing_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Tempus AI Shares Slide 12% as Q4 Results Disappoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Shares Slide 12% as Q4 Results Disappoint\n</h2>\n<h4 class=\"meta\">\n\n\n2025-02-25 07:28 GMT+8   <a href=\"https://www.investing.com/news/earnings/tempus-ai-shares-slide-7-as-q4-results-disappoint-93CH-3887329\"><strong>Investing</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Tempus AI reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.The artificial intelligence-powered precision medicine company posted revenue of $200.7 ...</p>\n<a href=\"https://www.investing.com/news/earnings/tempus-ai-shares-slide-7-as-q4-results-disappoint-93CH-3887329\">Source Link</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"https://www.investing.com/news/earnings/tempus-ai-shares-slide-7-as-q4-results-disappoint-93CH-3887329","article_id":"1161962625","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161962625","pubTimestamp":1740439713,"columns":[],"sourceInfo":{"source_id":"hk_investing_stock","name":"Investing"},"weMediaInfo":null,"summary":"$Tempus AI$ reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 4","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"第四季度业绩令人失望，Tempus AI股价下跌12%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1.1},"content_text":"Tempus AI reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.\"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year,\" said Eric Lefkofsky, Founder and CEO of Tempus.For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}